二级导航
招生简章
博士生导师
硕士生导师
培养方案
奖项介绍
研究生会
 
  陈崇

 

 【简历】

陈崇,教授,博士生导师,国家青年“千人计划”,国家自然科学基金委优秀青年基金获得者,四川省“千人计划”。
1999年毕业于北京大学生命科学学院获学士学位。2009 年毕业于(美国)密歇根大学细胞与发育生物学系,获博士学位。2010-2014年在(美国)冷泉港实验室/纪念斯隆-凯特琳癌症中心的Scott Lowe实验室从事博士后工作,研究表观遗传学基因在白血病发生中的作用及分子机理。2014 8 月起在四川大学华西医院/生物治疗国家重点实验室工作,受聘为血液肿瘤分子遗传学实验室主任,研究员。在肿瘤基因组学的基础上,我们利用shRNA干扰、CRISPR/Cas9基因组编辑、小鼠基因工程等技术研究肿瘤相关基因,特别是表观遗传学基因,在肿瘤发生发展中的作用,鉴定了多个重要的肿瘤驱动基因,例如组蛋白甲基转移酶MLL3Cancer Cell2014)、肿瘤代谢/表观遗传学相关的IDH突变(Genes & Development2013)等。我们还进一步研究了这些基因通过调控成体干细胞的组蛋白和DNA的甲基化等修饰影响其自我更新及分化从而导致肿瘤的分子及细胞机理。利用这些驱动基因,我们构建了新型的基因型肿瘤模型。在此基础上,我们通过shRNA文库、CRISPR/Cas9文库筛选鉴定了多个针对这些驱动基因的治疗靶标。我们最新的研究阐明了染色体异常在肿瘤发生发展中的作用(Liu and Chen et al., Nature 2016,共同第一)目前已在国际学术期刊NatureIF=41.5)、Cancer Cell IF=23.9)、Genes  Development (IF=12.6)Journal of Experimental Medicine (IF=15.2)Journal of Clinical Investigation (IF=15.4) 等发表SCI 论文20篇,引用1300余次。主持多项国家自然科学基金项目,参与多个美国国立卫生研究所R01、白血病与淋巴癌协会SCOR项目。获得了包括白血病与淋巴癌协会“职业发展奖(2011-2014the Leukemia & Lymphoma Society Career Development Program Award)、Keystone 研讨会“未来科学奖学金”(Keystone Symposia Future of Science Fund Scholarship 2014)等多个学术奖项。受邀在国际会议Acute Leukemia XV上做大会报告。
 
【受教育经历】
2003/7 – 2008/12 (美国)密歇根大学,博士
1995/9 – 1999/7 北京大学,学士
 
【研究工作经历】
2014/8-至今四川大学,华西医院/生物治疗国家重点实验室,血液肿瘤分子遗传学实验室主任,研究员(全职回国)
2011/8 – 2014/8 (美国)纪念斯隆-凯特琳癌症中心,博士后
2010/8 – 2011/7 (美国)冷泉港实验室,博士后
2009/1 – 2010/7 (美国)密歇根大学,博士后
 
【主要研究方向】
1)恶性肿瘤发生发展的分子机制;
2)成体干细胞的维持、恶性转变和衰老的分子机制;
3)表观遗传学在肿瘤和成体干细胞中的调控作用;
4)染色体异常的形成和作用机理。
 
【代表性论著】
1)        Liu, Yu, Chen, C. ,Xu, Z.,Scuoppo, C., Rillahan, CD.,Gao,J., Spitzer, B., Bosbach, B., Kastenhubr, ER., Baslan, T., Ackermann, S., Cheng, L., Wang, Q., Niu, T., Schultz, N., Levine, RL., Mills, AA.& Lowe, SW., Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.2016, Nature, 531:471-5. (#共同第一)
2)        Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW. MLL3 functions as a chromosome 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 2014 May 12; 25(5): 652-665. SCI       期刊论文 
Comment in: Will B. and Steidl U. Combinatorial Haplo-Deficient Tumor Suppression in 7q-Deficient Myelodysplastic Syndrome and Acute Myeloid Leukemia. Cancer Cell 2014 May 12; 25(5): 555-557
3)        Chen C, Liu Y, Lu C, Cross JR, Morris JP 4th, Shroff AS, Ward PS, Bradner JE, Thompson C, Lowe SW. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 2013 Sep 15;27(18):1974-85. SCI       期刊论文
Comment in: Lokody I. Metabolism: IDH2 drives cancer in vivo. Nat Rev Cancer. 2013 Oct 17. doi: 10.1038/nrc3619.
4)        Chen C, Liu Y, Liu Y*, Zheng P*. mTOR Activation Underlies Hematopoietic Stem Cell Defects in Autoimmune Diseases and Inflammation in the Mice. Journal of Clinical Investigation 2010 Nov 1;120(11):4091-101. *共同通讯)SCI   期刊论文
Comment in: Emerson SG and Garrett RW. Pharmacologic eigenvalues: beating the rap on bone marrow failure. Journal of Clinical Investigation 2010 Nov;120(11):3813-5
5)        Chen C. microRNAs in myelodysplastic syndromes: How much do we know and not know? Leuk Res. 2013 Mar;37(3):241-2. SCI       期刊论文
6)        Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Liu Y*, Zheng P*. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med. 2008 Sep 29;205(10):2397-408. *共同通讯)SCI   期刊论文
Comment in: Haneline L: F1000Prime Recommendation of [Chen C et al., J Exp Med 2008, 205(10):2397-408]. In F1000Prime, 21 Jan 2009; DOI: 10.3410/f.1145060.602188. F1000Prime.com/1145060#eval602188
7)        Chen C, Liu Y, Liu Y*, Zheng P*. 2009. mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells. Science Signaling 2009 Nov 24;2(98): ra75. *共同通讯)SCI      期刊论文
Comment in: Adler EM. 2009: signaling breakthroughs of the year. Science Signaling 2010 Jan 5;3(103):eg1
8)        Chen C, Liu Y, Liu Y, Zheng P. mTOR-mitochondria-ROS axis and stemness of the hematopoietic stem cells. Cell Cycle 2009 Apr 15;8(8):1158-60. SCI  期刊论文
9)        Li CS*, Chen C*, Zheng P*, Liu Y*.  Transgenic expression of P1A induced thymic tumor: a role for onco-fetal antigens in tumorigenesis. PLoS One. 2010 Oct 15;5(10):e13439. (* co-first author) *共同通讯)SCI 期刊论文
10)    Ye P.*, Liu Y.*, Chen C, Liu Y*., Zheng P*. An mTOR-Mdm2-Drosha Pathway for miRNA Biogenesis in Hematopoiesis and Cellular Response to Glucose Deprivation. Molecular Cell. 2015 Feb 19;57(4):708-20. (*: co-first author) *共同通讯)SCI     期刊论文
11)    Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram NP, Cross JR, Khanin R, Mason CE, Healey JH, Lowe SW, Schwartz GK, Melnick A, Thompson CB. Induction of sarcomas by mutant IDH2. Genes Dev. 2013 Sep 15;27(18):1986-98. SCI       期刊论文
Comment in: Lokody I. Metabolism: IDH2 drives cancer in vivo. Nat Rev Cancer. 2013 Oct 17. doi: 10.1038/nrc3619.
12)    Chen GY, Chen X, King S, Cavassani KA, Cheng J, Zheng X, Cao H, Yu H, Qu J, Fang D, Wu W, Bai XF, Liu JQ, Woodiga SA, Chen C, Sun L, Hogaboam CM, Kunkel SL, Zheng P*, Liu Y*. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol. 2011 May;29(5):428-35. *共同通讯)SCI      期刊论文
13)    Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, Lowe SW. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011 Aug 1;25(15):1628-40. SCI    期刊论文
14)    Wang LZ, Liu RH, Li W, Chen C, Katoh H, Chen GY, McNally BA, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y*, Zheng P*. 2009. Somatic Single-hits Inactivate the X-linked Tumor Suppressor FOXP3 in the Prostate. Cancer Cell 2009 Oct 6;16(4):336-46. *共同通讯)SCI   期刊论文
15)    Appelmann I, Rillahan CD, de Stanchina E, Carbonetti G, Chen C, Lowe SW, Sherr CJ.Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood. 2015 Feb 26;125(9):1444-51. SCI 期刊论文
16)    Wong C.*, Chen C, Liu Y*, Zheng P*. A critical Role for Regulated Wnt-Myc pathway in Naïve T cells Survival. J Immunol. 2015 Jan 1;194(1):158-67*共同通讯)SCI    期刊论文
17)    Wu Q, Liu Y, Chen C, Ikenoue T, Qiao Y, Li CS, Li W, Guan KL, Liu Y*, Zheng P*. The tuberous sclerosis complex-mammalian target of rapamycin pathway maintains the quiescence and survival of naive T cells. J Immunol. 2011 Aug 1;187(3):1106-12. *共同通讯)SCI 期刊论文
18)    Fennell M, Xiang Q, Hwang A, Chen C, Huang CH, Chen CC, Pelossof R, Garippa RJ. Impact of RNA-guided technologies for target identification and deconvolution. J Biomol Screen. 2014 Dec;19(10):1327-37. SCI 期刊论文
19)    Liu R, Wang L, Chen G, Katoh H, Chen C, Liu Y, Liu Y*, Zheng P*. FOXP3 Up-regulates p21 Expression by Inhibiting the Site-specific Association of HDAC-2 and -4 to the locus. Cancer Reserch 2009 Mar 15;69(6):2252-9. *共同通讯)SCI  期刊论文
20)    Liu R, Wang L, Chen C, Liu Y, Zhou P, Wang Y, Wang X, Turnbull J, Minassian BA, Liu Y*, Zheng P*. Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms. Mol Cell Biol. 2008 (23):7236-44. *共同通讯)SCI  期刊论文
21)    Chen GY, Chen C, Wang L, Chang X, Zheng P*, Liu Y*. Cutting edge: Broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. J Immunol. 2008 Apr 15;180(8):5163-6. *共同通讯)SCI    期刊论文
 
【联系方式】
邮箱:chen_chong@yahoo.com
生物治疗国家重点实验室 管理入口
地址:中国四川成都高朋大道科园四路一号 邮编:610041